The complex blocked EGF‐mediated activation of EGFR and inhibited tumours more efficiently than when the drug was used alone, whereas the binding between VHH and EGFR endowed the tumour selectivity of the conjugate.221. The gene discussed is EGF; the disease is neoplasm.